Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?

1 Feb 2012

Abstract excerpt

Adoptive T-cell transfer is recognized as an innovative treatment strategy for various malignant diseases.1,2 To improve the efficacy and sometimes the safety of this approach, T cells can be genetically manipulated to modify their antigen specificity, to enhance their in vivo survival and trafficking to specific tissues, or to be eliminated in the event of undesired toxic effects.3 γ-retroviral vectors are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22297819
DOI: 10.1038/mt.2011.288

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?PMID 22297819Read ↗

Current Non-Viral-Based Strategies to Manufacture CAR-T CellsSemantic proximity Read ↗

Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T CellsSemantic proximity Read ↗

Non-viral chimeric antigen receptor (CAR) T cells going viralSemantic proximity Read ↗

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapiesSemantic proximity Read ↗

Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology PatientsSemantic proximity Read ↗

Genetic in vivo engineering of human T lymphocytes in mouse modelsSemantic proximity Read ↗

Challenges in T cell receptor gene therapySemantic proximity Read ↗

Targeted gene delivery systems for T-cell engineeringSemantic proximity Read ↗

Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsSemantic proximity Read ↗

T-Cell Receptor Gene Therapy: Critical Parameters for Clinical SuccessSemantic proximity Read ↗

Lentiviral Vectors for CAR-T and Other Cell Therapy Products: A Microbiological and Biosafety PerspectiveSemantic proximity Read ↗

Non-viral transfection technologies for next-generation therapeutic T cell engineeringSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.